Comparative Pharmacology
Head-to-head clinical analysis: ORETON versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETON versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
ORETON vs TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
Testosterone enanthate is a prodrug of testosterone, which binds to androgen receptors, activating gene transcription that leads to development of male secondary sex characteristics and anabolic effects. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, promoting growth and development of female reproductive tissues and secondary sex characteristics.
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
1 to 2 mL of a combination product containing 90 mg testosterone enanthate and 4 mg estradiol valerate per mL intramuscularly every 4 weeks.
None Documented
None Documented
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Testosterone enanthate: 4-5 days (IM). Estradiol valerate: 2-3 days (IM). Steady-state reached in ~2-3 weeks.
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Testosterone enanthate and estradiol valerate are metabolized in the liver. Testosterone metabolites (e.g., androsterone, etiocholanolone) are conjugated and excreted renally (90%) and fecally (~10%). Estradiol valerate is hydrolyzed to estradiol, metabolized to estrone and estriol, conjugated, and excreted primarily renally (70-80%) with ~20% biliary/fecal.
Category C
Category D/X
Androgen
Androgen